


TITLE: Preparation of diaryl ureas as antiinflammatory agents  
 INVENTOR(S): Cirillo, Pier F.; Goldberg, Daniel R.; Hammach, Abdelhakim; Moss, Neil; Regan, John Robinson  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 67 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092576	A1	20021121	WO 2002-US14733	20020508 <--
W: AE, AU, BG, BR, CA, CN, CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2445003	A1	20021121	CA 2002-2445003	20020508 <--
AU 2002305500	A1	20021125	AU 2002-305500	20020508 <--
EP 1392661	A1	20040303	EP 2002-734324	20020508 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
JP 2004530690	T	20041007	JP 2002-589462	20020508 <--
US 20030008868	A1	20030109	US 2002-143322	20020510 <--
US 6852717	B2	20050208		
MX 2003010487	A	20040309	MX 2003-10487	20031114 <--
PRIORITY APPLN. INFO.:			US 2001-291425P	P 20010516 <--
			WO 2002-US14733	W 20020508 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
ED Entered STN: 22 Nov 2002				
GI				



I

AB The title diaryl ureas, useful in pharmaceutic compns. for treating a cytokine mediated diseases or conditions involving inflammation such as chronic inflammatory diseases, were prepared Thus, treating 4-(2-chloropyrimidin-4-yloxy)naphthalen-1-ylamine with Et<sub>3</sub>N in DMF followed by addition of Et<sub>4</sub>NCN, and treatment of the resulting nitrile with phosgene, and reacting the intermediate with 5-tert-butyl-o-anisidine afforded the urea I.  
 IC ICM C07D239-34  
 ICS A61K031-505; C07D251-42; C07D239-47; C07D417-12; C07D401-12; C07D231-40; A61P029-00  
 CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1

IT	285983-44-0P	473269-90-8P	473269-96-4P	473271-63-5P	473271-65-7P
	473271-70-4P	473271-82-8P	473271-86-2P	473271-87-3P	473271-90-8P
	473271-91-9P	473271-96-4P	473272-06-9P	473272-08-1P	473272-09-2P
	473272-15-0P	473272-16-1P	476009-04-8P	476009-05-9P	476009-07-1P
	476009-08-2P	476009-10-6P	476009-12-8P	476009-16-2P	476009-18-4P
	476009-19-5P	476009-21-9P	476009-22-0P	476009-23-1P	476009-25-3P
	476009-27-5P	476009-28-6P	476009-30-0P	476009-34-4P	476009-38-8P
	476009-40-2P	476009-42-4P	476009-43-5P	476009-46-8P	476009-48-0P
	476009-49-1P	476009-52-6P	476009-54-8P	476009-56-0P	476009-58-2P
	476009-60-6P	476009-62-8P	476009-63-9P	476009-65-1P	476009-66-2P
	476009-67-3P	476009-68-4P	476009-70-8P	476009-71-9P	476009-72-0P
	476009-74-2P	<del>476009-78-6P</del>	<del>476009-80-0P</del>		
	<del>476009-82-2P</del>	476009-84-4P	476009-87-7P	476009-89-9P	
	476009-91-3P	476009-93-5P	476009-95-7P	476009-97-9P	476010-05-6P
	476010-09-0P	476010-11-4P	476010-14-7P	476010-16-9P	476010-17-0P
	476010-19-2P	476010-20-5P	476010-22-7P	476010-24-9P	476010-26-1P
	476010-28-3P	476010-30-7P	476010-32-9P	476010-34-1P	476010-36-3P
	476010-38-5P	476010-40-9P	476010-42-1P	476010-44-3P	476010-46-5P
	476010-48-7P	476010-50-1P	476010-52-3P	476010-53-4P	476010-54-5P
	476010-56-7P	476010-58-9P	476010-60-3P	476010-62-5P	476010-64-7P
	476010-65-8P	476010-68-1P	476010-72-7P	476010-74-9P	476010-77-2P
	476010-79-4P	476010-81-8P	476010-84-1P	476010-86-3P	476010-88-5P
	476010-90-9P	476010-92-1P	476010-96-5P	476010-98-7P	476010-99-8P
	476011-01-5P	476011-03-7P	476011-05-9P	476011-06-0P	476011-08-2P
	476011-10-6P	476011-12-8P	476011-14-0P	476011-16-2P	476011-18-4P
	476011-20-8P	476011-22-0P	476011-24-2P	476011-26-4P	476011-28-6P
	476011-30-0P	476011-32-2P	476011-34-4P	476011-36-6P	476011-37-7P
	476011-39-9P	476011-41-3P	476011-43-5P	<del>476011-45-7P</del>	
	476011-47-9P	476011-49-1P	476011-51-5P	476011-53-7P	476011-55-9P
	476012-73-4P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);  
THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)  
(preparation of diaryl ureas as antiinflammatory agents)


IT 476009-78-6P 476009-80-0P 476009-82-2P  
476011-45-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);  
THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); USES (Uses)  
(preparation of diaryl ureas as antiinflammatory agents)


RN 476009-78-6 HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[[2-(2-methoxyphenyl)-4-pyrimidinyl]oxy]-1-naphthalenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 476009-80-0 HCAPLUS  
CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[[2-(3-methoxyphenyl)-4-pyrimidinyl]oxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 476009-82-2 HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methoxyphenyl]-N'-[4-[(2-phenyl-4-pyrimidinyl)oxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 476011-45-7 HCAPLUS

CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[4-[[2-(2-methoxyphenyl)-4-pyrimidinyl]oxy]-1-naphthalenyl]amino]carbonyl]amino]phenyl]- (CA INDEX NAME)



PAGE 1-A

